<DOC>
	<DOCNO>NCT00079482</DOCNO>
	<brief_summary>The purpose study determine whether CEP-701 give sequence induction chemotherapy increase proportion patient relapse acute myeloid leukemia ( AML ) achieve second complete remission ( CR ) .</brief_summary>
	<brief_title>Study CEP-701 ( Lestaurtinib ) Patients With Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>Patients randomly assign chemotherapy alone receive second course induction chemotherapy soon clinically indicate ; patient randomly assign receive chemotherapy plus sequential lestaurtinib lestaurtinib withheld 3 day ( 72 hour ) start second 5-day course chemotherapy resume lestaurtinib treatment 2 day ( 48 hour ) final administration second course chemotherapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Inclusion criterion : cytological confirmation AML ; relapse disease follow first CR 1 month ( 30days ) 24 month ( 730days ) . The time first relapse study entry ( start first course induction chemotherapy ) must longer 30days ; confirmation FLT3 activate mutation positive status point initial relapse ; age 18 year old ; write informed consent ; ability understand comply study restriction ; comorbid condition would limit life expectancy le 3 month ; ECOG Performance Score 0 , 1 , 2 ; woman must neither pregnant lactating , either nonchildbearing potential use adequate contraception negative pregnancy test study entry Exclusion criterion : bilirubin &gt; 2x ULN ; ALT/AST &gt; 3x ULN ; serum creatinine &gt; 1.5 mg/dL ; rest ejection fraction leave ventricle l &lt; 45 % ( applies patient schedule receive mitoxantrone , etoposide , cytarabine [ MEC ] ; untreated progressive infection ; physical psychiatric cdtn may compromise participation study ; know CNS involvement AML ; previous treatment FLT3 inhibitor ; require current treatment HIV protease inhibitor ; active GI ulceration bleeding ; use investigational drug expect cleared start CEP701 treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>AML</keyword>
</DOC>